|
1.
|
Siegel R, Naishadham D and Jemal A: Cancer
statistics, 2013. CA Cancer J Clin. 63:11–30. 2013. View Article : Google Scholar
|
|
2.
|
McGuire WP III and Markman M: Primary
ovarian cancer chemotherapy: current standards of care. Br J
Cancer. 89(Suppl 3): S3–S8. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
3.
|
Stewart JJ, White JT, Yan X, et al:
Proteins associated with Cisplatin resistance in ovarian cancer
cells identified by quantitative proteomic technology and
integrated with mRNA expression levels. Mol Cell Proteomics.
5:433–443. 2006. View Article : Google Scholar
|
|
4.
|
Mellish KJ, Barnard CF, Murrer BA and
Kelland LR: DNA-binding properties of novel cis- and trans
platinum-based anticancer agents in 2 human ovarian carcinoma cell
lines. Int J Cancer. 62:717–723. 1995. View Article : Google Scholar : PubMed/NCBI
|
|
5.
|
O’Neill CF, Koberle B, Masters JR and
Kelland LR: Gene-specific repair of Pt/DNA lesions and induction of
apoptosis by the oral platinum drug JM216 in three human ovarian
carcinoma cell lines sensitive and resistant to cisplatin. Br J
Cancer. 81:1294–1303. 1999.
|
|
6.
|
Ohmichi M, Hayakawa J, Tasaka K, Kurachi H
and Murata Y: Mechanisms of platinum drug resistance. Trends
Pharmacol Sci. 26:113–116. 2005. View Article : Google Scholar
|
|
7.
|
Wang Z, Li Y, Kong D, et al: Acquisition
of epithelial-mesenchymal transition phenotype of
gemcitabine-resistant pancreatic cancer cells is linked with
activation of the notch signaling pathway. Cancer Res.
69:2400–2407. 2009. View Article : Google Scholar
|
|
8.
|
Meng RD, Shelton CC, Li YM, et al:
gamma-Secretase inhibitors abrogate oxaliplatin-induced activation
of the Notch-1 signaling pathway in colon cancer cells resulting in
enhanced chemosensitivity. Cancer Res. 69:573–582. 2009. View Article : Google Scholar
|
|
9.
|
Kuroda Y, Murakami N, Morota M, et al:
Impact of concurrent chemotherapy on definitive radiotherapy for
women with FIGO IIIb cervical cancer. J Radiat Res. 53:588–593.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
10.
|
Lai EC: Notch signaling: control of cell
communication and cell fate. Development. 131:965–973. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
11.
|
Artavanis-Tsakonas S, Rand MD and Lake RJ:
Notch signaling: cell fate control and signal integration in
development. Science. 284:770–776. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
12.
|
Nickoloff BJ, Osborne BA and Miele L:
Notch signaling as a therapeutic target in cancer: a new approach
to the development of cell fate modifying agents. Oncogene.
22:6598–6608. 2003. View Article : Google Scholar
|
|
13.
|
Suwannarurk K, Bhamarapravatana K,
Thaweekul Y, Mairaing K, Poomtavorn Y and Pattaraarchachai J: A
1-year experience with liquid-based and conventional papanicolaou
smear in Thammasat University Hospital. J Med Assoc Thai. 94(Suppl
7): S47–S51. 2011.PubMed/NCBI
|
|
14.
|
Wagner U, Marth C, Largillier R, et al:
Final overall survival results of phase III GCIG CALYPSO trial of
pegylated liposomal doxorubicin and carboplatin vs paclitaxel and
carboplatin in platinum-sensitive ovarian cancer patients. Br J
Cancer. 107:588–591. 2012. View Article : Google Scholar
|
|
15.
|
Doll CM, Aquino-Parsons C, Pintilie M, et
al: The significance of tumoral ERCC1 status in patients with
locally advanced cervical cancer treated with chemoradiation
therapy: a multicenter clinicopathologic analysis. Int J Radiat
Oncol Biol Phys. 85:721–727. 2013. View Article : Google Scholar
|
|
16.
|
Miyamura T, Masuzaki H and Ishimaru T:
Conservative treatment of a cervical pregnancy with local
methotrexate injection. Int J Gynaecol Obstet. 45:62–63. 1994.
View Article : Google Scholar : PubMed/NCBI
|
|
17.
|
Rose SL, Kunnimalaiyaan M, Drenzek J and
Seiler N: Notch 1 signaling is active in ovarian cancer. Gynecol
Oncol. 117:130–133. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
18.
|
Chu D, Wang W, Xie H, et al: Notch1
expression in colorectal carcinoma determines tumor differentiation
status. J Gastrointest Surg. 13:253–260. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
19.
|
Wang M, Wang J, Wang L, Wu L and Xin X:
Notch1 expression correlates with tumor differentiation status in
ovarian carcinoma. Med Oncol. 27:1329–1335. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
20.
|
Yoo J, Choi JY, Moon SH, et al: Prognostic
significance of volume-based metabolic parameters in uterine
cervical cancer determined using 18F-fluorodeoxyglucose positron
emission tomography. Int J Gynecol Cancer. 22:1226–1233. 2012.
|
|
21.
|
Sorosky JI: Endometrial cancer. Obstet
Gynecol. 120:383–397. 2012. View Article : Google Scholar
|
|
22.
|
Wang M, Wu L, Wang L and Xin X:
Down-regulation of Notch1 by gamma-secretase inhibition contributes
to cell growth inhibition and apoptosis in ovarian cancer cells
A2780. Biochem Biophys Res Commun. 393:144–149. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
23.
|
Hopfer O, Zwahlen D, Fey MF and Aebi S:
The Notch pathway in ovarian carcinomas and adenomas. Br J Cancer.
93:709–718. 2005. View Article : Google Scholar
|
|
24.
|
Tsang RY, Al-Fayea T and Au HJ: Cisplatin
overdose: toxicities and management. Drug Saf. 32:1109–1122. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
25.
|
Jones ME, van Leeuwen FE, Hoogendoorn WE,
et al: Endometrial cancer survival after breast cancer in relation
to tamoxifen treatment: pooled results from three countries. Breast
Cancer Res. 14:R912012. View
Article : Google Scholar : PubMed/NCBI
|
|
26.
|
Ma K, Wen HW and Liao QP: Expression of
Notch3 and Notch intracellular domain in ovarian carcinoma and
effect of N-[N-(3,5-difluorophenyl) acetyl-L-alanyl]-S-phenyl
glycine t-butyl ester on ovarian carcinoma cell. Zhonghua Fu Chan
Ke Za Zhi. 45:921–926. 2010.In Chinese.
|
|
27.
|
Ma XG, Wang YM, Xue FX, et al:
Clinicalpathological characteristics of Lynch syndrome related
epithelial ovarian cancer. Zhonghua Fu Chan Ke Za Zhi. 47:201–204.
2012.In Chinese.
|
|
28.
|
van den Akker T, Beltman J, Leyten J, et
al: The WHO maternal near miss approach: consequences at Malawian
District level. PLoS One. 8:e548052013.PubMed/NCBI
|
|
29.
|
Masuda S, Kumano K, Suzuki T, et al: Dual
antitumor mechanisms of Notch signaling inhibitor in a T-cell acute
lymphoblastic leukemia xenograft model. Cancer Sci. 100:2444–2450.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
30.
|
Kohorn EI: Imaging practices in the
diagnosis and management of gestational trophoblastic disease: an
assessment. J Reprod Med. 57:207–210. 2012.PubMed/NCBI
|
|
31.
|
Sun XM, Wen HW, Chen CL and Liao QP:
Expression of Notch intracellular domain in cervical cancer and
effect of DAPT on cervical cancer cell. Zhonghua Fu Chan Ke Za Zhi.
44:369–373. 2009.In Chinese.
|
|
32.
|
Korsmeyer SJ: Regulators of cell death.
Trends Genet. 11:101–105. 1995. View Article : Google Scholar
|
|
33.
|
Drexler HC: Programmed cell death and the
proteasome. Apoptosis. 3:1–7. 1998. View Article : Google Scholar
|
|
34.
|
Ito M: Factors controlling cyclin B
expression. Plant Mol Biol. 43:677–690. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
35.
|
Friedrich K, Wieder T, Von Haefen C, et
al: Overexpression of caspase-3 restores sensitivity for
drug-induced apoptosis in breast cancer cell lines with acquired
drug resistance. Oncogene. 20:2749–2760. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
36.
|
Williams J, Lucas PC, Griffith KA, et al:
Expression of Bcl-xL in ovarian carcinoma is associated with
chemoresistance and recurrent disease. Gynecol Oncol. 96:287–295.
2005. View Article : Google Scholar
|
|
37.
|
Beel AJ and Sanders CR: Substrate
specificity of gamma-secretase and other intramembrane proteases.
Cell Mol Life Sci. 65:1311–1334. 2008. View Article : Google Scholar : PubMed/NCBI
|
